JP2024506291A - 吸入用のフューリンインヒビターの製剤 - Google Patents
吸入用のフューリンインヒビターの製剤 Download PDFInfo
- Publication number
- JP2024506291A JP2024506291A JP2023547188A JP2023547188A JP2024506291A JP 2024506291 A JP2024506291 A JP 2024506291A JP 2023547188 A JP2023547188 A JP 2023547188A JP 2023547188 A JP2023547188 A JP 2023547188A JP 2024506291 A JP2024506291 A JP 2024506291A
- Authority
- JP
- Japan
- Prior art keywords
- free form
- pharmaceutical composition
- compound
- certain embodiments
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163145363P | 2021-02-03 | 2021-02-03 | |
| US63/145,363 | 2021-02-03 | ||
| PCT/US2022/015098 WO2022169962A1 (en) | 2021-02-03 | 2022-02-03 | Formulation of furin inhibitor for inhalation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024506291A true JP2024506291A (ja) | 2024-02-13 |
| JP2024506291A5 JP2024506291A5 (https=) | 2025-02-06 |
Family
ID=80446118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023547188A Pending JP2024506291A (ja) | 2021-02-03 | 2022-02-03 | 吸入用のフューリンインヒビターの製剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240307374A1 (https=) |
| EP (1) | EP4288052A1 (https=) |
| JP (1) | JP2024506291A (https=) |
| KR (1) | KR20230142752A (https=) |
| CN (1) | CN117222410A (https=) |
| AU (1) | AU2022215580A1 (https=) |
| CA (1) | CA3205921A1 (https=) |
| IL (1) | IL304858A (https=) |
| WO (1) | WO2022169962A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102023126563A1 (de) * | 2023-09-28 | 2025-04-03 | Philipps-Universität Marburg, Körperschaft des öffentlichen Rechts | Hemmstoffe der Proproteinkonvertase Furin, Verfahren zu deren Herstellung und Verwendung |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012518663A (ja) * | 2009-02-26 | 2012-08-16 | グラクソ グループ リミテッド | ４−｛（１ｒ）−２−［（６−｛２−［（２，６−ジクロロベンジル）オキシ］エトキシ｝ヘキシル）アミノ］−１−ヒドロキシエチル｝−２−（ヒドロキシメチル）フェノールを含む医薬製剤 |
| JP2015500268A (ja) * | 2011-12-09 | 2015-01-05 | ラボラトワール・エスエムベ・ソシエテ・アノニム | アゾール誘導体の吸入用乾燥粉末製剤 |
| JP2017505784A (ja) * | 2014-02-14 | 2017-02-23 | レスピバート・リミテツド | 抗炎症化合物としての芳香族複素環化合物 |
| WO2019215341A1 (en) * | 2018-05-11 | 2019-11-14 | Glaxosmithkline Intellectual Property Development Limited | Furin inhibitors |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ535425A (en) | 2002-03-13 | 2008-05-30 | Biogen Idec Inc | Anti-alphavbeta6 antibodies |
-
2022
- 2022-02-03 CN CN202280026916.7A patent/CN117222410A/zh active Pending
- 2022-02-03 KR KR1020237029502A patent/KR20230142752A/ko active Pending
- 2022-02-03 CA CA3205921A patent/CA3205921A1/en active Pending
- 2022-02-03 WO PCT/US2022/015098 patent/WO2022169962A1/en not_active Ceased
- 2022-02-03 AU AU2022215580A patent/AU2022215580A1/en not_active Abandoned
- 2022-02-03 EP EP22705656.1A patent/EP4288052A1/en active Pending
- 2022-02-03 US US18/275,531 patent/US20240307374A1/en active Pending
- 2022-02-03 JP JP2023547188A patent/JP2024506291A/ja active Pending
- 2022-02-03 IL IL304858A patent/IL304858A/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012518663A (ja) * | 2009-02-26 | 2012-08-16 | グラクソ グループ リミテッド | ４−｛（１ｒ）−２−［（６−｛２−［（２，６−ジクロロベンジル）オキシ］エトキシ｝ヘキシル）アミノ］−１−ヒドロキシエチル｝−２−（ヒドロキシメチル）フェノールを含む医薬製剤 |
| JP2015500268A (ja) * | 2011-12-09 | 2015-01-05 | ラボラトワール・エスエムベ・ソシエテ・アノニム | アゾール誘導体の吸入用乾燥粉末製剤 |
| JP2017505784A (ja) * | 2014-02-14 | 2017-02-23 | レスピバート・リミテツド | 抗炎症化合物としての芳香族複素環化合物 |
| WO2019215341A1 (en) * | 2018-05-11 | 2019-11-14 | Glaxosmithkline Intellectual Property Development Limited | Furin inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| DOUGLAS, LISA E.J. ET AL.: ""Furin Inhibition as a Mechanism to Reduce Aberrant ENaC‐Mediated Sodium Transport and Rehydrate t", THE FASEB JOURNAL, vol. 33, no. 1, JPN6025042960, April 2019 (2019-04-01), ISSN: 0005712173 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3205921A1 (en) | 2022-08-11 |
| KR20230142752A (ko) | 2023-10-11 |
| EP4288052A1 (en) | 2023-12-13 |
| IL304858A (en) | 2023-10-01 |
| WO2022169962A1 (en) | 2022-08-11 |
| US20240307374A1 (en) | 2024-09-19 |
| AU2022215580A9 (en) | 2024-05-09 |
| CN117222410A (zh) | 2023-12-12 |
| AU2022215580A1 (en) | 2023-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI800567B (zh) | 包含血漿激肽釋放酶抑制劑之劑型 | |
| CN103201262B (zh) | 自分泌运动因子抑制剂及其用途 | |
| JP5461405B2 (ja) | 嚢胞性線維症膜コンダクタンス制御因子の調節因子 | |
| CN104039775B (zh) | Atp‑结合盒转运蛋白的调节剂 | |
| EP3856164B1 (en) | Morphic forms of complement factor d inhibitors | |
| RU2707887C2 (ru) | Производное дигидроиндолизинона | |
| CA3069226A1 (en) | Methods of treatment for cystic fibrosis | |
| TW201221128A (en) | Crystalline forms of a factor Xa inhibitor | |
| CN102421742A (zh) | 3-戊基苯乙酸的盐及其药物用途 | |
| BR112021014956A2 (pt) | Composições e compostos terapêuticos | |
| JP2024506291A (ja) | 吸入用のフューリンインヒビターの製剤 | |
| CN101583614A (zh) | 用于治疗呼吸道合胞体病毒感染的多环试剂 | |
| BR112021008462A2 (pt) | compostos e composições terapêuticas | |
| JP7078722B2 (ja) | 血漿カリクレイン阻害剤を含む剤形 | |
| RU2799824C2 (ru) | Ингибиторы фурина | |
| RU2827865C2 (ru) | Производные хинолина для применения при лечении воспалительных заболеваний | |
| IL303227B2 (en) | Combined pumped storage power plant - desalination plant on the beach (ocean), or river, or lake | |
| BR112020010154B1 (pt) | Forma de dosagem sólida oral, seus usos e seus métodos de preparação | |
| KR20230121762A (ko) | (5s)-사이클로프로필-5-[3-[(3s)-4-(3,5-디플루오로페닐)-3-메틸-피페라진-1-일]-3-옥소-프로필]이미다졸리딘-2,4-디온의 고체 형태 | |
| HK40025124B (zh) | 注射用组合物 | |
| HK40035163A (en) | Dosage forms comprising a plasma kallikrein inhibitor | |
| HK40035163B (en) | Dosage forms comprising a plasma kallikrein inhibitor | |
| HK1143363A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| HK1143363B (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| HK1201827B (en) | Modulators of atp-binding cassette transporters |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250129 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250129 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20251014 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251021 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260410 |